Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced today key strategic promotions within the organization. Continued organic and acquisition growth combined with upcoming important product and service launches has led the organization to put in place a new strategic structure.

"Decision Resources, Inc.'s spectacular growth has been fueled by strong organic growth and astute, aggressive acquisitions," said Peter Hoenigsberg, CEO of Decision Resources, Inc. "We are reorganizing our various portfolio businesses around our end markets by dividing the structure into two segments - Biopharma and Medical Technology."

Mark Bard, formerly the president of Manhattan Research, A Decision Resources, Inc. company, joins the Decision Resources, Inc. senior team as Chief Commercialization Officer. Mr. Bard's new role will focus on working in tandem with the leadership teams at the various business units to drive overall revenue for the organization.

"Mark brings extensive dynamic leadership and experience within the healthcare industry to Decision Resources, Inc. through his development and growth of Manhattan Research, a leading provider of insight into the impact of electronic media on physician and consumer brand recognition and retention," said Mr. Hoenigsberg. "Mark will be a critical member of the senior team responsible for driving the company's organic growth beyond our current, ambitious projections."

The following promotions supplement the existing corporate team:

Jason LaBonte, PhD has been promoted to Chief Operating Officer of the newly formed Portfolio Planning segment within the Biopharma business unit which includes Decision Resources and Arlington Medical Resources, both Decision Resources, Inc. portfolio companies. Dr. LaBonte brings his experience in the product, new product and commercial sides of the business to his new role.

Joe Farris has been promoted to President of Manhattan Research which leads the Brand segment of the Biopharma business unit at Decision Resources, Inc. Mr. Farris will spearhead the company's drive to create important solutions for pharmaceutical brand teams via exciting new product initiatives and bolt-on acquisitions.

Matthew Bonner, MD has been appointed to Vice President of Research for Decision Resources, Inc. In his new role, Dr. Bonner will be accountable for the integrity and quality of all intellectual property for the organization. He will also play a pivotal role in Decision Resources, Inc. product development.

Elizabeth Marshall has been promoted to Vice President of Marketing for Decision Resources, Inc. Ms. Marshall will be responsible for strategic marketing for Decision Resources, Inc. and all the companies within the Decision Resources, Inc. portfolio.

"As the organization grows, we want to put in place a structure that allows for disciplined accountability and at the same time, fosters the entrepreneurial spirit and creativity that all the companies under the Decision Resources, Inc. umbrella possess," Mr. Hoenigsberg said. "The individuals that have been appointed to these critical roles and their teams will achieve that goal."

About Decision Resources, Inc.

Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources, Inc. currently consists of six companies: Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries; Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues; Fingertip Formulary, the leading provider of access to and insight into formulary data in the United States; HealthLeaders-InterStudy, the leading provider of managed care market intelligence; Manhattan Research, the leading provider of access to physician and consumer opinions on the global healthcare market; and Millennium Research Group, the global authority on medical device market intelligence. For more information, please visit

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,

For the Treatment of Chronic Tophaceous Gout, a Drug That Resolves Tophi in Less Than One Year Would Become the Patient Share Leader in the U.S. and Europe

View Now